There are currently 365 clinical trials in Stanford, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Stanford University, Stanford University School of Medicine, Stanford University Medical Center and Stanford Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
NCT03964480
Recruiting
This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection of data to predict the prognosis of patients with the more frequent subtypes of PTCL. It is a prospective, longitudinal, international, observational study of patients with newly diagnosed peripheral T-cell lymphoma aiming to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Stanford University, Stanford, California
Conditions: Peripheral T-Cell Lymphoma
Register for Updates
Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer
NCT04840472
Recruiting
The primary purpose of the study is to assess the safety of 111In-panitumumab as a molecular imaging agent in patients with Head and Neck Squamous Cell Carcinoma. The secondary objective is to compare sensitivity and specificity of identifying sentinel lymph nodes by systemic injection of 111In-panitumumab prior to Day of Surgery versus conventional local injection with an optical dye at the time of surgery.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
05/02/2025
Locations: Stanford University, Stanford, California
Conditions: Head and Neck Cancer
Register for Updates
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
NCT00373347
Recruiting
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Liver Cancer
Register for Updates
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
NCT01034033
Recruiting
The purpose of this study is to try to understand the biology of development of breast, ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk for these diseases. The influence of environmental factors on cancer development in individuals and families will be studied. The efficacy of treatments for these diseases will be evaluated.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Breast Cancer, Ovarian Cancer, Gynecologic Cancers, Ovarian/Peritoneal/Fallopian Cancer
Register for Updates
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
NCT03909282
Recruiting
The purpose of this pilot study is to compare by pathological findings surgical excision versus neoadjuvant radiotherapy followed by delayed surgical excision of ductal carcinoma in situ (DCIS)
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford University, Stanford, California
Conditions: Ductal Breast Carcinoma in Situ
Register for Updates
Leveraging Mindsets to Improve Health and Wellbeing in Patients With Cancer
NCT04020029
Recruiting
Primary Objectives: Mindsets have been rigorously studied in the domains of development, education, and more recently, in health and disease. However, there are no large-scale longitudinal studies of the mindsets held by cancer patients and how they may affect treatment outcomes, physical health, and psychological well-being. This randomized, single-blind, treatment-as-usual (TAU) control study aims to assess (1) mindsets at four time points spanning from the point of diagnosis to six weeks pos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford University, Stanford, California
Conditions: Cancer
Register for Updates
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
NCT04609592
Recruiting
The purpose of this study is to learn about the feasibility and safety of using Peptide Receptor Radionuclide Therapy (PRRT) before and after surgical removal of a tumor. PRRT treatment is based on the administration of a radioactive product, 177-Lu DOTA-0-Tyr3-Octreotate (Lutathera®) and its use before and after surgery is thought to increase the overall survival benefit for patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors GEP-NETs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford Cancer Institute Palo Alto, Stanford, California
Conditions: Gastroenteropancreatic Neuroendocrine Tumor
Register for Updates
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
NCT05987644
Recruiting
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will receive alectinib alone. Those in Phase 2, Arm B will receive SRS + alectinib. A maximum of 25 cycles (2 years) of alectinib may be administered on study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford University, Stanford, California
Conditions: Lung Cancer, NSCLC, Brain Metastases
Register for Updates
Measuring Surgical Recovery After Radical Cystectomy
NCT03193970
Recruiting
The intent of this study is to establish a registry of post-surgical outcomes in patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating institutions. The goals of this initiative are to obtain a detailed baseline of multiple patient-reported outcomes (PRO) and clinician-reported outcomes (CRO) as well as various presenting conditions associated with them, so that future quality improvement interventions can be evaluated accurately as to their relative contribut... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Stanford University, Stanford, California
Conditions: Bladder Cancer
Register for Updates
Bedside Ultrasound of Gastric Contents in Pediatric Populations
NCT03520374
Recruiting
Perioperative aspiration of gastric contents is a rare but serious adverse event. The risk of aspiration can be estimated by perioperative evaluation of stomach contents with ultrasound using a validated technique and scoring system. A lack of knowledge or familiarity is frequently cited by anesthesia providers as a rationale for not performing perioperative ultrasound assessments. The purpose of this study is to determine whether novice ultrasonography users (medical students, undergraduates, o... Read More
Gender:
ALL
Ages:
Between 2 years and 60 years
Trial Updated:
04/30/2025
Locations: LPCH/SHC, Stanford, California
Conditions: Gastric Contents
Register for Updates
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
NCT05395624
Recruiting
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/30/2025
Locations: Stanford University, Stanford, California
Conditions: Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Register for Updates
Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
NCT06234098
Recruiting
This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of AT-1965 in patients with advanced, refractory or recurrent solid tumors (nonresectable and/or metastatic) including mTNBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: CBCC Global Research Site 003, Stanford, California
Conditions: Solid Tumor
Register for Updates